Reactive Oxygen®
"the next major breakthrough in topical and deep surgical wound healing and infection control."

Matoke Holdings’ mission is to build a disruptive market entry:

“To create a range of Reactive Oxygen® delivery systems to become the first choice range for tissue care clinicians, both for topical and for deep surgical interventions, to control potential or actual infections, whilst positively driving wound repair”

Over 160 years, wound infection control and healing technology has not moved at the pace of other medical care breakthroughs.

The net result is a huge issue of long term patient suffering. In the UK alone there are 2 million unresolved chronic wounds which are physically and socially debilitating and which come with a huge economic burden. Failure to heal these wounds can often lead to amputation and further disability. In the UK alone there are 25 lower limb amputations every day for unresolved diabetic ulcers.

Read More

Extraordinary infection control

Prevent & destroy biofilms

Stimulate tissue regeneration

Stimulate the immune system

Partners

Matoke Holdings is actively looking to work with global health care companies, to accelerate the technology to make a real impact on global health.

To discuss further please contact our CEO Ian Staples: istaples@matokeholdings.com

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

World Health Organization logo logotype 1200px PublicHealthEngland.svg national+biofilms+innovation+centre download 1280px University of Southampton Logo.svg

Investors

Matoke Holdings would like to speak to potential investors to help develop the technology.

To discuss further please contact our CEO Ian Staples: istaples@matokeholdings.com